
Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsGSK Aligns With CTTQ to Expand Access to Bepirovirsen in ChinaGSK has partnered with Sino Biopharmaceutical’s subsidiary CTTQ to accelerate access to bepirovirsen in mainland China.Fact-Checked
Mergers & AcquisitionsOncotelic-Lunai N2B Deal Gains Momentum Amid Rising Focus on CNS Drug DeliveryThe May 6 agreement grants Lunai Bioworks worldwide rights to Oncotelic’s N2B platform for Alzheimer’s disease and biodefense applications, highlighting increasing biotech interest in intranasal CNS drug-delivery technologies…Fact-Checked
Mergers & AcquisitionsRoche to Acquire PathAI in Up to $1.05 Billion Digital Pathology DealRoche has agreed to acquire PathAI in a deal that could strengthen its digital pathology and AI-enabled diagnostics portfolio.Fact-Checked
Mergers & AcquisitionsGSK Partners With Halozyme to Develop Subcutaneous ADC TherapiesHalozyme Therapeutics has signed a global collaboration and license agreement with GSK to develop potential subcutaneous formulations for multiple oncology therapies using ENHANZE® technology.Fact-Checked
Mergers & AcquisitionsGSK Licenses SiranBio’s siRNA Candidate SA030 in Up to $1 Billion DealGSK has signed a worldwide exclusive licensing agreement with Suzhou Siran Biotechnology for SA030, a Phase I long-acting siRNA therapy targeting ALK7 for metabolic and vascular disease, excluding…Fact-Checked
Mergers & AcquisitionsBayer to Acquire Perfuse Therapeutics in Up to USD 2.45 Billion Ophthalmology DealBayer has agreed to fully acquire Perfuse Therapeutics, expanding its ophthalmology pipeline with PER-001, an investigational endothelin receptor antagonist designed to target ischemia-related retinal diseases.Fact-Checked
Mergers & AcquisitionsHalozyme Licenses Hypercon Technology to Oruka Therapeutics for ORKA-001Halozyme Therapeutics and Oruka Therapeutics have entered a global collaboration to use Hypercon™ drug delivery technology with ORKA-001, Oruka’s Phase 1 IL-23-targeting psoriasis candidate.Fact-Checked
Mergers & AcquisitionsArrowhead Takes Aim at MASH Genetics with Madrigal Licensing DealArrowhead Pharmaceuticals and Madrigal Pharmaceuticals enter a global deal for ARO-PNPLA3, an investigational RNAi therapy targeting PNPLA3 mutations in MASH, supported by Phase 1 data showing significant liver…Fact-Checked
Mergers & AcquisitionsEvotec–Almirall Hit Preclinical Milestone for Skin Disease TherapyEvotec SE and Almirall S.A. have nominated a small-molecule preclinical development candidate (PDC) targeting immune-mediated inflammatory skin diseases with high unmet need.Fact-Checked
Mergers & AcquisitionsBioCryst and Neopharmed Gentili Sign Navenibart Deal to Support 2027 FilingBioCryst licenses navenibart to Neopharmed Gentili in Europe in a $345M deal, supporting Phase 3 development and regional commercialization strategy in hereditary angioedema.Fact-Checked
Mergers & AcquisitionsUCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune DealMagnific UCB to acquire Candid Therapeutics for up to $2.2B, adding BCMA-targeting T-cell engager cizutamig to strengthen its autoimmune disease…Fact-Checked
Mergers & AcquisitionsUCB Taps IMIDomics to Power Its Precision Medicine EngineUCB has acquired IMIDomics’ Patient Insights Business, securing access to a large, curated dataset and biobank to support precision medicine and accelerate development in immune-mediated diseases.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.